Skip to main content

Coats Lonnel's Form 4 filing

Blueprint Medicines CorpBPMC · filed Nov 22, 2024

Accession no.
0001415889-24-027545
Filed
Nov 22, 2024
Trade date
Nov 20-21, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.87M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Coats LonnelCIK 0001612528Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 20, 2024Common StockMOption exerciseAcquired+7,500$69.79+$523,42520,754Direct
Nov 20, 2024Common StockMOption exerciseAcquired+1,312$76.24+$100,026.8822,066Direct
Nov 20, 2024Common StockSSaleDisposed−4,500$93.15F2−$419,17517,566Direct
Nov 20, 2024Common StockSSaleDisposed−5,287$94.24F3−$498,246.8812,279Direct
Nov 20, 2024Common StockSSaleDisposed−213$94.99F4−$20,232.8712,066Direct
Nov 21, 2024Common StockSSaleDisposed−9,824$94.87−$932,002.882,242Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 20, 2024Common StockMOption exerciseDisposed−7,500$0.00$00Direct
Nov 20, 2024Common StockMOption exerciseDisposed−1,312$0.00$03,188Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is an average price. The shares were sold in multiple transactions ranging from $92.71 to $93.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).

Referenced by the price of 1 transaction in Table I.

F3

The price reported is an average price. The shares were sold in multiple transactions ranging from $93.74 to $94.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).

Referenced by the price of 1 transaction in Table I.

F4

The price reported is an average price. The shares were sold in multiple transactions ranging from $94.74 to $95.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)